Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381376568> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4381376568 abstract "The frequency of prediabetes as well as the optimal method to identify glucose abnormalities in morbid obesity (MO) is subject to debate. We, therefore, evaluated the frequency of prediabetes and the optimal method for its respective diagnosis in a large cohort with MO. We included 1.626 patients with MO (age 34±10 years, BMI 44.6± 7.0 kg/m², 74.3% women). All patients without overt type 2 diabetes (T2D) underwent a 75g OGTT. Prediabetes was diagnosed according to ADA criteria. Demographic, cardiovascular risk-markers, insulin levels and renal parameters were assessed. We excluded 421 (25.9%) patients due to T2D. Regarding prediabetes, 339 patients (28.1%) fulfilled the fasting glucose criterion, 240 the 2-hour postprandial criterion (19.9%), and 594 patients the HbA1c criterion (49.2%). 56 patients (4.6%) fulfilled all three criteria, 810 (67.2%) had at least one criterion. 933 (77.4%) patients fulfilled either the fasting glucose or the HbA1c criterion, and 834 (69.2%) either the 2h postprandial or HbA1c criterion. Patient's characteristics are depicted in table 1. The results of our study suggest that fasting glucose or HbA1c are sufficient to diagnose prediabetes. This is particularly of interest since postoperative changes in gut anatomy following bariatric surgery might render a postoperative OGTT invalid for follow-up, whereas fasting glucose or HbA1c are not affected. Disclosure J.Brix: Advisory Panel; Boehringer Ingelheim Pharma GmbH&Co.KG, Eli Lilly and Company, Novo Nordisk, Speaker's Bureau; AstraZeneca, Eli Lilly and Company, Novo Nordisk. V.Parzer: None. S.L.Huber: None. B.Ludvik: Advisory Panel; Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim Pharma GmbH&Co.KG, Amgen Inc., AstraZeneca, Research Support; Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim Pharma GmbH&Co.KG, Amgen Inc., AstraZeneca, Speaker's Bureau; Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim Pharma GmbH&Co.KG, Amgen Inc., AstraZeneca." @default.
- W4381376568 created "2023-06-21" @default.
- W4381376568 creator A5004811392 @default.
- W4381376568 creator A5071354955 @default.
- W4381376568 creator A5071523351 @default.
- W4381376568 creator A5091812033 @default.
- W4381376568 date "2023-06-20" @default.
- W4381376568 modified "2023-09-24" @default.
- W4381376568 title "1711-P: Assessment of Prediabetes in Patients with Morbid Obesity (MO)" @default.
- W4381376568 doi "https://doi.org/10.2337/db23-1711-p" @default.
- W4381376568 hasPublicationYear "2023" @default.
- W4381376568 type Work @default.
- W4381376568 citedByCount "0" @default.
- W4381376568 crossrefType "journal-article" @default.
- W4381376568 hasAuthorship W4381376568A5004811392 @default.
- W4381376568 hasAuthorship W4381376568A5071354955 @default.
- W4381376568 hasAuthorship W4381376568A5071523351 @default.
- W4381376568 hasAuthorship W4381376568A5091812033 @default.
- W4381376568 hasConcept C126322002 @default.
- W4381376568 hasConcept C134018914 @default.
- W4381376568 hasConcept C141071460 @default.
- W4381376568 hasConcept C2777180221 @default.
- W4381376568 hasConcept C2777185836 @default.
- W4381376568 hasConcept C2778199505 @default.
- W4381376568 hasConcept C2779306644 @default.
- W4381376568 hasConcept C2779668308 @default.
- W4381376568 hasConcept C2780609358 @default.
- W4381376568 hasConcept C511355011 @default.
- W4381376568 hasConcept C555293320 @default.
- W4381376568 hasConcept C71924100 @default.
- W4381376568 hasConcept C72563966 @default.
- W4381376568 hasConceptScore W4381376568C126322002 @default.
- W4381376568 hasConceptScore W4381376568C134018914 @default.
- W4381376568 hasConceptScore W4381376568C141071460 @default.
- W4381376568 hasConceptScore W4381376568C2777180221 @default.
- W4381376568 hasConceptScore W4381376568C2777185836 @default.
- W4381376568 hasConceptScore W4381376568C2778199505 @default.
- W4381376568 hasConceptScore W4381376568C2779306644 @default.
- W4381376568 hasConceptScore W4381376568C2779668308 @default.
- W4381376568 hasConceptScore W4381376568C2780609358 @default.
- W4381376568 hasConceptScore W4381376568C511355011 @default.
- W4381376568 hasConceptScore W4381376568C555293320 @default.
- W4381376568 hasConceptScore W4381376568C71924100 @default.
- W4381376568 hasConceptScore W4381376568C72563966 @default.
- W4381376568 hasIssue "Supplement_1" @default.
- W4381376568 hasLocation W43813765681 @default.
- W4381376568 hasOpenAccess W4381376568 @default.
- W4381376568 hasPrimaryLocation W43813765681 @default.
- W4381376568 hasRelatedWork W2039255545 @default.
- W4381376568 hasRelatedWork W2045145511 @default.
- W4381376568 hasRelatedWork W2064185418 @default.
- W4381376568 hasRelatedWork W2080135029 @default.
- W4381376568 hasRelatedWork W2089449544 @default.
- W4381376568 hasRelatedWork W2129737421 @default.
- W4381376568 hasRelatedWork W2307995317 @default.
- W4381376568 hasRelatedWork W2758620209 @default.
- W4381376568 hasRelatedWork W2769137505 @default.
- W4381376568 hasRelatedWork W4220718597 @default.
- W4381376568 hasVolume "72" @default.
- W4381376568 isParatext "false" @default.
- W4381376568 isRetracted "false" @default.
- W4381376568 workType "article" @default.